5 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 5 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Public Storage, PSA
Summary: Public Storage's principal business activities include the ownership and operation of self-storage facilities and other related operations including tenant reinsurance and third-party self-storage management. They acquire, develop, own and operate self-storage facilities, which offer storage spaces for lease on a month-to-month basis, for personal and business use. They are the largest owner and operator of self-storage facilities in the United States.
- Last Price: $274.64
- Price Change: $0.62, 0.23%
- Yearly Gain: -4.54%
- Market Cap: $48.26B
- P/E Ratio: 24.94
Here are 3rd party ratings for PSA:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 33% (168 out of 250)
What is the sentiment on the street regarding Public Storage ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Balanced
- Investor Sentiment: Negative
- Hedge Fund signal: Medium Risk
If you are interested in PSA or any stocks within the Real Estate sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on PSA before you decide to make any investment.
Click here for chart >>
Glaukos Corporation, GKOS
Summary: Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.
- Last Price: $113.17
- Price Change: $0.17, 0.15%
- Yearly Gain: 69.09%
- Market Cap: $5.70B
- P/E Ratio: -39.3
Here are 3rd party ratings for GKOS:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 41% (148 out of 250)
What is the sentiment on the street regarding Glaukos Corporation ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in GKOS or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on GKOS before you decide to make any investment.
Click here for chart >>
ALX Oncology Holdings Inc., ALXO
Summary: ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.
- Last Price: $8.56
- Price Change: $-0.11, -1.27%
- Yearly Gain: -2.17%
- Market Cap: $445.98M
- P/E Ratio: -2.31
Here are 3rd party ratings for ALXO:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: Buy, Top 32% (80 out of 250)
What is the sentiment on the street regarding ALX Oncology Holdings Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in ALXO or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ALXO before you decide to make any investment.
Click here for chart >>
Acrivon Therapeutics, Inc. Common Stock, ACRV
Summary: Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics. The company's lead candidate includes ACR-368. Acrivon Therapeutics Inc. is based in WATERTOWN, Mass.
- Last Price: $7.40
- Price Change: $-0.16, -2.12%
- Yearly Gain: -39.69%
- Market Cap: $228.49M
- P/E Ratio: -2.56
Here are 3rd party ratings for ACRV:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: Buy, Top 32% (80 out of 250)
What is the sentiment on the street regarding Acrivon Therapeutics, Inc. Common Stock ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in ACRV or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ACRV before you decide to make any investment.
Click here for chart >>
-, ATYR
Summary: aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.
- Last Price: $1.95
- Price Change: $0.02, 1.04%
- Yearly Gain: 12.72%
- Market Cap: $134.57M
- P/E Ratio: -
Here are 3rd party ratings for ATYR:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 32% (80 out of 250)
What is the sentiment on the street regarding - ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: -
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Risk Not Mentioned
If you are interested in ATYR or any stocks within the - sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ATYR before you decide to make any investment.
Click here for chart >>
Thanks for reading!